In last trading session, Cara Therapeutics Inc. (NASDAQ:CARA) saw 2.9 million shares changing hands with its beta currently measuring 0.88. Company’s recent per share price level of $2.34 trading at $0.27 or 13.04% at ring of the bell on the day assigns it a market valuation of $130.53M. That closing price of CARA’s stock is at a discount of -447.44% from its 52-week high price of $12.81 and is indicating a premium of 27.35% from its 52-week low price of $1.70. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.07 million shares which gives us an average trading volume of 1.31 million if we extend that period to 3-months.
For Cara Therapeutics Inc. (CARA), analysts’ consensus is at an average recommendation of an Overweight while assigning it a mean rating of 1.60. Splitting up the data highlights that, out of 6 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 5 see the stock as a Buy. 1 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.51 in the current quarter.
Cara Therapeutics Inc. (NASDAQ:CARA) trade information
Upright in the green during last session for gaining 13.04%, in the last five days CARA remained trading in the green while hitting it’s week-highest on Friday, 09/15/23 when the stock touched $2.34 price level, adding 5.65% to its value on the day. Cara Therapeutics Inc.’s shares saw a change of -78.21% in year-to-date performance and have moved 21.88% in past 5-day. Cara Therapeutics Inc. (NASDAQ:CARA) showed a performance of -20.14% in past 30-days. Number of shares sold short was 1.55 million shares which calculate 2.83 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $15.50 to the stock, which implies a rise of 84.9% to its current value. Analysts have been projecting $3.00 as a low price target for the stock while placing it at a high target of $25.00. It follows that stock’s current price would drop -968.38% in reaching the projected high whereas dropping to the targeted low would mean a loss of -28.21% for stock’s current value.
Cara Therapeutics Inc. (CARA) estimates and forecasts
Statistics highlight that Cara Therapeutics Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -59.52% of value to its shares in past 6 months, showing an annual growth rate of -21.38% while that of industry is 12.00. Apart from that, the company came lowering its revenue forecast for fiscal year 2023. The company is estimating its revenue growth to decrease by -18.60% in the current quarter and calculating 25.00% increase in the next quarter. This year revenue growth is estimated to fall -3.60% from the last financial year’s standing.
5 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $10.69 million for the same. And 5 analysts are in estimates of company making revenue of $16.6 million in the next quarter that will end on Dec 2023. Company posted $10.81 million and $3.26 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to shrink by -1.10% while estimating it to be 409.00% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -9.10% during past 5 years.
Cara Therapeutics Inc. is more likely to be releasing its next quarterly report in October and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Cara Therapeutics Inc. (NASDAQ:CARA)’s Major holders
Insiders are in possession of 14.71% of company’s total shares while institution are holding 64.61 percent of that, with stock having share float percentage of 75.75%. Investors also watch the number of corporate investors in a company very closely, which is 64.61% institutions for Cara Therapeutics Inc. that are currently holding shares of the company. Blackrock Inc. is the top institutional holder at CARA for having 3.7 million shares of worth $10.48 million. And as of Jun 29, 2023, it was holding 6.85% of the company’s outstanding shares.
The second largest institutional holder is Vanguard Group Inc, which was holding about 2.59 million shares on Jun 29, 2023. The number of shares represents firm’s hold over 4.80% of outstanding shares, having a total worth of $7.34 million.
On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Jun 29, 2023, the former fund manager was holding 1.35 million shares of worth $3.83 million or 2.50% of the total outstanding shares. The later fund manager was in possession of 1.11 million shares on Jul 30, 2023, making its stake of worth around $3.71 million in the company or a holder of 2.06% of company’s stock.